Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Molecular Imaging and Biology (2018) DOI: 10.1007/s11307-018-1252-5
- Keyword
-
Positronen-Emissions-Tomografie
- Event
-
Veröffentlichung
- (where)
-
Würzburg
- (who)
-
Universität Würzburg
- (when)
-
2018
- Creator
-
Wolf, Herta
Ilhan, Harun
Lehner, Sebastian
Papp, László
Zsótér, Norbert
Schatka, Imke
Muegge, Dirk O.
Javadi, Mehrbod S.
Higuchi, Takahiro
Buck, Andreas K.
Bartenstein, Peter
Bengel, Frank M.
Essler, Markus
Lapa, Constantin Frederik Victor
Bundschuh, Ralph A.
- URN
-
urn:nbn:de:bvb:20-opus-167168
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:42 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wolf, Herta
- Ilhan, Harun
- Lehner, Sebastian
- Papp, László
- Zsótér, Norbert
- Schatka, Imke
- Muegge, Dirk O.
- Javadi, Mehrbod S.
- Higuchi, Takahiro
- Buck, Andreas K.
- Bartenstein, Peter
- Bengel, Frank M.
- Essler, Markus
- Lapa, Constantin Frederik Victor
- Bundschuh, Ralph A.
- Universität Würzburg
Time of origin
- 2018
Other Objects (12)
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
Peptide receptor radionuclide therapy for sarcoidosis
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
New radiolabelled somatostatin receptor ligands for diagnosis and therapy
Octreotate: a new somatostatin analogue for tumor imaging and radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Somatostatin receptor PET/CT in the management of patients with neuroendocrine tumors
Peptide receptor radionuclide Therapy (PRRT) : efficacy and safety with special consideration of high-risk constellations
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
Peptide receptor radionuclide therapy for sarcoidosis
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
New radiolabelled somatostatin receptor ligands for diagnosis and therapy
Octreotate: a new somatostatin analogue for tumor imaging and radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Somatostatin receptor PET/CT in the management of patients with neuroendocrine tumors
Peptide receptor radionuclide Therapy (PRRT) : efficacy and safety with special consideration of high-risk constellations
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
Peptide receptor radionuclide therapy for sarcoidosis
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
New radiolabelled somatostatin receptor ligands for diagnosis and therapy
Octreotate: a new somatostatin analogue for tumor imaging and radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Somatostatin receptor PET/CT in the management of patients with neuroendocrine tumors